Skip to content
Peptide Atlas
All peptides

Retatrutide

Tier 1 · Human trials
Also known as LY3437943 · LY-3437943

Strongest evidence is Tier 1: multiple randomized controlled trials including the NEJM phase 2 obesity trial, phase 2 type 2 diabetes trials, the phase 3 TRANSCEND-T2D-1 trial, and phase 3 TRIUMPH data. Supporting evidence spans meta-analyses (one a preprint), animal studies, mechanistic reviews, and lower-tier vendor/blog sources. Retatrutide remains investigational and is not FDA approved; the largest weight-loss figures come from Drugs.com summaries of phase 3 TRIUMPH data rather than peer-reviewed primary reports.

Half-life
~144 h
Routes
Subcutaneous injection
Goals
Weight loss / obesity management · Glycemic control / type 2 diabetes · Metabolic/fatty liver health · Cardiometabolic risk reduction
Cost / mg
Not recorded

How it works

Multiple clinical trial reports describe retatrutide (LY3437943) as a single peptide that switches on three gut and metabolic hormone receptors at once: the GIP receptor, the GLP-1 receptor, and the glucagon receptor. According to Eli Lilly and mechanistic reviews, activating GLP-1 boosts glucose-dependent insulin release, slows stomach emptying and increases feelings of fullness; activating GIP also aids insulin release and lipid handling; and activating the glucagon receptor raises energy expenditure, thermogenesis and fat mobilization while reducing food intake. The combined result reported across trials is dose-dependent weight loss and improved blood-sugar control. A fatty diacid attached to the peptide extends its half-life to roughly 6 days, allowing once-weekly injection.

Overview

Overview

Retatrutide (also known as LY3437943 or LY-3437943) is described across multiple clinical trial reports as a single-peptide agonist of three receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon (GCG) receptor. Drugs.com describes it as an investigational triple hormone receptor agonist being developed for weight loss in obesity and overweight people with weight-related problems, given as a once-weekly subcutaneous injection, and states it is not FDA approved and only available to clinical trial participants.

Receptor pharmacology

The NEJM phase 2 trial reports that, compared with endogenous receptor ligands, retatrutide is less potent at the human glucagon (by a factor of 0.3) and GLP-1 (by a factor of 0.4) receptors and more potent at the human GIP receptor (by a factor of 8.9). A mechanism review notes it exhibits relatively stronger agonism at the GIP receptor while maintaining attenuated activation of GLP-1 and glucagon receptors, and in vitro work found LY3437943 shows balanced GCGR and GLP-1R activity but more GIPR activity. Per Eli Lilly medical information and mechanistic reviews, GLP-1 receptor activation enhances glucose-dependent insulin secretion, modulates glucagon secretion, delays gastric emptying and increases satiety; GIP activation facilitates glucose-dependent insulin secretion and regulates lipid metabolism; and glucagon receptor agonism increases hepatic glucose production, energy expenditure, thermogenesis and lipid mobilization while reducing food intake. Eli Lilly states that preclinical and early-phase clinical data suggest retatrutide may reduce food intake, enhance energy expenditure, improve lipid metabolism and glucose homeostasis, and reduce inflammation.

Weight-loss efficacy

The NEJM phase 2 obesity trial (338 adults enrolled, 51.8% men) administered subcutaneous retatrutide once weekly for 48 weeks at 1, 4, 8 or 12 mg, with a lower 2 mg starting dose for titration. At 48 weeks the least-squares mean body weight change was −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg) and −24.2% (12 mg), versus −2.1% for placebo. At 48 weeks, weight reduction of 15% or more occurred in 60% (4 mg), 75% (8 mg) and 83% (12 mg) versus 2% for placebo. A review reports retatrutide 12 mg once weekly produced weight loss of up to 22.1% (95% CI 19.3–24.9%) after 48 weeks, describing it as a premarket agent for long-term weight management.

Drugs.com reports that in the phase 3, 80-week TRIUMPH-1 trial (2,339 adults with obesity/overweight without type 2 diabetes), adults on retatrutide 12 mg lost an average of 70.3 lbs (28.3%), 9 mg lost 64.4 lbs (25.9%), 4 mg lost 47.2 lbs (19.0%) and placebo lost 5.5 lbs (2.2%), with 45.3% at 12 mg achieving 30% or more weight loss. A protocol paper describes TRIUMPH as four phase 3 multicenter randomized double-blind studies (over 5,800 participants enrolled) of weekly subcutaneous retatrutide versus placebo for obesity and two related complications—obstructive sleep apnea (Apnea-Hypopnea Index) and knee osteoarthritis (WOMAC pain subscale). These largest phase 3 figures come from Drugs.com summaries rather than peer-reviewed primary reports.

Type 2 diabetes

The 40-week phase 3 TRANSCEND-T2D-1 trial (537 participants randomized; mean age 48.8 years, baseline HbA1c 7.9%, BMI 35.8 kg/m²) tested retatrutide 4, 9 or 12 mg as monotherapy versus placebo. Mean HbA1c change from baseline was −1.69% (4 mg), −1.86% (9 mg) and −1.94% (12 mg) versus −0.81% for placebo, with mean percentage bodyweight change of −11.5%, −13.9% and −15.3% versus −2.6% for placebo. A phase 2 trial randomized 281 participants with type 2 diabetes to retatrutide or 1.5 mg dulaglutide, reporting 24-week HbA1c changes as large as −2.02% (12 mg escalation) versus −0.01% for placebo and −1.41% for dulaglutide; a Lancet review notes retatrutide produced greater bodyweight reduction than the selective GLP-1 receptor agonist dulaglutide, and that TRANSCEND-T2D-1 is the first phase 3 trial of retatrutide for type 2 diabetes. Drugs.com reports TRIUMPH-2 (1,152 participants with type 2 diabetes and obesity/overweight) showed up to 49.6 lbs (20.8%) weight loss over 80 weeks with a 1.5% A1C reduction at 12 mg.

Broader metabolic effects

A randomized, double-blind, placebo-controlled trial of 98 participants reported mean relative change in liver fat at 24 weeks of −42.9% (1 mg) to −82.4% (12 mg) versus +0.3% for placebo, with normal liver fat (<5%) achieved by up to 86% at 12 mg. The phase 2b TRANSCEND-CKD study randomized 146 adults to once-weekly retatrutide up to 12 mg or placebo, with change in measured glomerular filtration rate by iohexol clearance as the primary objective. Drugs.com reports TRIUMPH-3 (1,949 participants with severe obesity and established heart disease) showed up to 55.8 lbs (22.6%) weight loss over 80 weeks, with the 12 mg dose lowering triglycerides by 37.0%, non-HDL cholesterol by 16.5% and systolic blood pressure by 9.3 mmHg. Reviews describe retatrutide being explored for obesity, type 2 diabetes, non-alcoholic/metabolic fatty liver disease, chronic kidney disease and other metabolic dysregulation, with some early data suggesting it may lead to even greater weight loss than tirzepatide.

Meta-analyses

A meta-analysis of 3 studies (640 patients, 510 prescribed retatrutide) found significant reductions versus placebo in body weight (WMD −10.66 kg), BMI (WMD −4.53 kg/m²) and waist circumference (WMD −6.61 cm), and increased proportions achieving ≥5% (RR 2.92), ≥10% (RR 9.32), ≥15% (RR 18.40) and ≥20% (RR 16.61) weight reduction. A separate meta-analysis of 3 RCTs (878 patients) reported a −14.33% body weight reduction. A Research Square preprint meta-analysis (not yet peer-reviewed) reported reductions of HbA1c 0.9%, fasting blood glucose 21.87 mg/dL, body weight 10.66 kg and BMI 4.55 kg/m² versus placebo.

Regulatory and development status

Drugs.com states retatrutide is not FDA approved and available only to clinical trial participants. A vendor blog reports it remains in phase 3 trials, with analysts expecting regulatory submission around 2026 and potential market availability in late 2026 or 2027—these are promotional forecasts rather than trial findings. A review noted retatrutide is among 14 ongoing phase 3 trials of novel antiobesity drugs, and that completed phase 2 incretin-based therapy trials showed mean percent weight loss of 7.4% to 24.2%.

What the research shows

234 findings extracted from the 25 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 92 human trial findings, 10 human study findings, 6 animal findings, 5 expert opinion findings and 1 theoretical finding.

  • human trialThe novel triple-hormone agonist retatrutide led to substantial weight reduction in patients with overweight, obesity and/or type 2 diabetes1

  • human trialRetatrutide was associated with a significant improvement of metabolic markers in patients with overweight, obesity, and/or T2D1

  • human trialRetatrutide significantly reduced body weight compared with placebo (WMD -10.66 kg; 95% CI -17.63, −3.69)1

  • human trialRetatrutide significantly reduced body mass index compared with placebo (WMD -4.53 kg/m2; 95% CI -7.51, −1.55)1

  • human trialRetatrutide significantly reduced waist circumference compared with placebo (WMD -6.61 cm; 95% CI -13.17, −0.05)1

  • human trialRetatrutide significantly increased the proportion of patients who achieved a weight reduction of ≥5% (RR 2.92; 95% CI 2.17–3.93)1

  • human trialRetatrutide significantly increased the proportion of patients who achieved a weight reduction of ≥10% (RR 9.32; 95% CI 4.56–19.06)1

  • human trialRetatrutide significantly increased the proportion of patients who achieved a weight reduction of ≥15% (RR 18.40; 95% CI 6.00–56.42)1

Show 106 more findings

  • human trialRetatrutide significantly increased the proportion of patients who achieved a weight reduction of ≥20% (RR 16.61; 95% CI 4.17–66.12)1

  • human trialRetatrutide significantly reduced body weight2

  • human trialWhen compared with placebo, retatrutide achieved similar changes in baseline fasting glucose levels3

  • human trialPhase I and II clinical trials show dose-dependent weight loss3

  • human trialPhase I and II clinical trials show reductions in Glycated Hemoglobin (HbA1c) levels3

  • human trialPhase I and II clinical trials show improvements in liver steatosis and diabetic kidney disease3

  • human trialOngoing Phase III trials, such as the TRIUMPH studies, aim to further evaluate retatrutide's long-term safety and efficacy in diverse patient populations3

  • human trialAdults on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks in TRIUMPH-14

  • human trial45.3% achieved 30% or more weight loss in TRIUMPH-1, a threshold previously reserved for bariatric surgery4

  • human trialTRIUMPH-1 is a Phase 3, 80-week, randomized, double-blind, placebo-controlled trial of retatrutide in 2,339 adults with obesity or overweight and at least one weight-related comorbidity, without type 2 diabetes4

  • human trialRetatrutide 9 mg resulted in 64.4 lbs (25.9%) body weight lost in TRIUMPH-14

  • human trialRetatrutide 4 mg resulted in 47.2 lbs (19.0%) body weight lost in TRIUMPH-14

  • human trialPlacebo resulted in 5.5 lbs (2.2%) body weight lost in TRIUMPH-14

  • human trialAdults with type 2 diabetes lost up to an average of 49.6 lbs (20.8%) in TRIUMPH-2 over 80 weeks4

  • human trialAdults with severe obesity and heart disease lost up to an average of 55.8 lbs (22.6%) in TRIUMPH-3 over 80 weeks4

  • human trialIn TRIUMPH-2, adults with type 2 diabetes and obesity or overweight had A1C reduction of 1.5% at retatrutide 12 mg dose4

  • human trialTRIUMPH-2 enrolled 1,152 participants with an average starting weight of 234.6 lbs (106.4 kg) and an average A1C of 7.7%4

  • human trialIn TRIUMPH-3, participants at the 12 mg dose saw triglycerides fall by an average of 37.0%, non-HDL cholesterol by 16.5%, systolic blood pressure by 9.3 mmHg4

  • human trialTRIUMPH-3 enrolled 1,949 participants with severe obesity (BMI of 35 or higher) and established heart disease with an average starting weight of 245.6 lbs (111.4 kg)4

  • human trialAt 24 weeks, least-squares mean percentage change in body weight was −7.2% in the 1-mg group, −12.9% in the combined 4-mg group, −17.3% in the combined 8-mg group, and −17.5% in the 12-mg group, compared with −1.6% in the placebo group5

  • human trialAt 48 weeks, least-squares mean percentage change in body weight was −8.7% in the 1-mg group, −17.1% in the combined 4-mg group, −22.8% in the combined 8-mg group, and −24.2% in the 12-mg group, compared with −2.1% in the placebo group5

  • human trialAt 48 weeks, weight reduction of 5% or more occurred in 92% of participants receiving 4 mg, 100% of those receiving 8 mg, 100% of those receiving 12 mg, and 27% of those receiving placebo5

  • human trialAt 48 weeks, weight reduction of 10% or more occurred in 75% of participants receiving 4 mg, 91% receiving 8 mg, 93% receiving 12 mg, and 9% receiving placebo5

  • human trialAt 48 weeks, weight reduction of 15% or more occurred in 60% of participants receiving 4 mg, 75% receiving 8 mg, 83% receiving 12 mg, and 2% receiving placebo5

  • human trialIn a phase 1b trial involving participants with type 2 diabetes, treatment with retatrutide resulted in a placebo-adjusted least-squares mean weight reduction of 8.96 kg (approximately 10%) in the highest-dose (12-mg) group after 12 weeks5

  • human trialAt 24 weeks, least-squares mean percentage change in body weight: 1 mg group -7.2%, 4 mg group -12.9%, 8 mg group -17.3%, 12 mg group -17.5%, placebo -1.6%5

  • human trialAt 48 weeks, least-squares mean percentage change in body weight: 1 mg group -8.7%, 4 mg group -17.1%, 8 mg group -22.8%, 12 mg group -24.2%, placebo -2.1%5

  • human trialAt 48 weeks, weight reduction of 5% or more occurred in 92% (4 mg), 100% (8 mg), 100% (12 mg), and 27% (placebo)5

  • human trialAt 48 weeks, weight reduction of 10% or more occurred in 75% (4 mg), 91% (8 mg), 93% (12 mg), and 9% (placebo)5

  • human trialAt 48 weeks, weight reduction of 15% or more occurred in 60% (4 mg), 75% (8 mg), 83% (12 mg), and 2% (placebo)5

  • human trialIn a phase 2 clinical trial in 281 people with type 2 diabetes (NCT04867785), treatment with retatrutide resulted in greater bodyweight reduction compared with a selective GLP-1 receptor agonist (dulaglutide)6

  • human trialMean change from baseline in HbA1c concentration was -1.69% with retatrutide 4 mg7

  • human trialMean change from baseline in HbA1c concentration was -1.86% with retatrutide 9 mg7

  • human trialMean change from baseline in HbA1c concentration was -1.94% with retatrutide 12 mg7

  • human trialMean change from baseline in HbA1c concentration was -0.81% with placebo7

  • human trialTreatment difference versus placebo of -0.88% (95% CI -1.18 to -0.59) with retatrutide 4 mg7

  • human trialTreatment difference versus placebo of -1.04% (95% CI -1.32 to -0.76) with retatrutide 9 mg7

  • human trialTreatment difference versus placebo of -1.12% (95% CI -1.39 to -0.85) with retatrutide 12 mg7

  • human trialMean percentage change from baseline in bodyweight was -11.5% with retatrutide 4 mg7

  • human trialMean percentage change from baseline in bodyweight was -13.9% with retatrutide 9 mg7

  • human trialMean percentage change from baseline in bodyweight was -15.3% with retatrutide 12 mg7

  • human trialMean percentage change from baseline in bodyweight was -2.6% with placebo7

  • human trialRetatrutide reduced weight and hemoglobin A1c (HbA1c) in individuals with obesity and type 2 diabetes9

  • human trialThe primary objective is to evaluate the effect of retatrutide versus placebo on change in measured glomerular filtration rate (mGFR) by iohexol clearance from baseline to Week 249

  • human trialTRIUMPH clinical development program evaluates safety and efficacy of retatrutide for treatment of obesity and two related complications-obstructive sleep apnea (OSA) and knee osteoarthritis (OA)10

  • human trialOver 5800 participants enrolled in TRIUMPH trials10

  • human trialPrimary endpoint for weight management is percent change in body weight10

  • human trialPrimary endpoint for OSA is change in Apnea-Hypopnea Index10

  • human trialPrimary endpoint for knee OA includes change in Western Ontario and McMaster Universities Osteoarthritis Index pain subscale score10

  • human trialRetatrutide significantly reduced hemoglobin A1c (HbA1c) by 0.9%11

  • human trialRetatrutide reduced fasting blood glucose (FBG) by 21.87 mg/dL11

  • human trialRetatrutide reduced body weight by 10.66 kg11

  • human trialRetatrutide reduced body mass index (BMI) by 4.55 kg/m211

  • human trialRetatrutide modestly reduced blood pressure compared with placebo11

  • human trialRetatrutide significantly reduced lipid profiles compared with placebo11

  • human trialRetatrutide showed robust reductions in body weight and clinically meaningful improvements in glycemic control and cardiometabolic measures for patients with overweight/obesity and/or T2D11

  • human trialRetatrutide (12 mg once weekly) produced greater weight loss of up to 22.1% (95% CI, 19.3% to 24.9%) after 48 weeks12

  • human trialRetatrutide is among 14 ongoing phase 3 trials on novel antiobesity pharmacotherapies13

  • human trialCompleted phase 2 trials on incretin-based therapies showed a mean percent weight loss of 7.4% to 24.2%13

  • human trialEarly data suggests retatrutide may lead to even greater weight loss than tirzepatide14

  • human trialRetatrutide (GLP-1, GIP, and glucagon receptor triple agonist) induces ∼15-24% weight loss in adults with overweight and obesity15

  • human trialRetatrutide causes beneficial impacts on blood pressure, cholesterol, blood glucose, and insulin15

  • human trialA 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8 and 12 mg, respectively16

  • human trialIn a randomized, double-blind, placebo-controlled trial with 98 participants, mean relative change from baseline in liver fat at 24 weeks was -42.9% (1 mg), -57.0% (4 mg), -81.4% (8 mg), -82.4% (12 mg) and +0.3% (placebo), all P < 0.001 versus placebo16

  • human trialAt 24 weeks, normal liver fat (<5%) was achieved by 27% (1 mg), 52% (4 mg), 79% (8 mg), 86% (12 mg) and 0% (placebo) of participants16

  • human trialRetatrutide showed clinically meaningful glucose-lowering and bodyweight-lowering efficacy in a phase 1 study17

  • human trialAt 24 weeks, HbA1c change from baseline was -0.43% for the 0.5 mg group17

  • human trialAt 24 weeks, HbA1c change from baseline was -1.39% for the 4 mg escalation group17

  • human trialAt 24 weeks, HbA1c change from baseline was -1.30% for the 4 mg group17

  • human trialAt 24 weeks, HbA1c change from baseline was -1.99% for the 8 mg slow escalation group17

  • human trialAt 24 weeks, HbA1c change from baseline was -1.88% for the 8 mg fast escalation group17

  • human trialAt 24 weeks, HbA1c change from baseline was -2.02% for the 12 mg escalation group17

  • human trialAt 24 weeks, HbA1c change from baseline was -0.01% for the placebo group17

  • human trialAt 24 weeks, HbA1c change from baseline was -1.41% for the 1.5 mg dulaglutide group17

  • human trialBodyweight decreased by 3.19% at 36 weeks for the 0.5 mg group17

  • human trialBodyweight decreased by 7.92% at 36 weeks for the 4 mg escalation group17

  • human trialBodyweight decreased by 10.37% at 36 weeks for the 4 mg group17

  • human trialBodyweight decreased by 16.81% at 36 weeks for the 8 mg slow escalation group17

  • human trialBodyweight decreased by 16.34% at 36 weeks for the 8 mg fast escalation group17

  • human trialBodyweight decreased by 16.94% at 36 weeks for the 12 mg escalation group17

  • human trialBodyweight decreased by 3.00% at 36 weeks for placebo17

  • human trialBodyweight decreased by 2.02% at 36 weeks for 1.5 mg dulaglutide17

  • human trialA reduction in body weight persisted up to day 43 after a single dose18

  • human trialRetatrutide has been studied in clinical trials for obesity and diabetes outcomes19

  • human studyPhase I and II clinical trials show dose-dependent weight loss3

  • human studyPhase I and II clinical trials show reductions in Glycated Hemoglobin (HbA1c) levels3

  • human studyPhase I and II clinical trials show improvements in liver steatosis and diabetic kidney disease3

  • human studyOngoing Phase III trials, such as the TRIUMPH studies, aim to further evaluate retatrutide's long-term safety and efficacy in diverse patient populations3

  • human studyGIP and GLP-1 receptor agonist tirzepatide has shown superior effects on glycaemic control and bodyweight compared with selective GLP-1 receptor agonism (dulaglutide and semaglutide)6

  • human studyWeight reduction efficacy of GLP-1 and GIP/GLP-1 agents is generally attenuated in trial participants with type 2 diabetes compared with participants without type 2 diabetes6

  • human studyRetatrutide has shown promise in glycaemic control and weight loss8

  • human studyParticipants in Phase 2 trials lost up to 24% of their body weight in under a year21

  • human studyIn Phase 2 studies, participants taking higher doses of retatrutide lost an average of up to 24% of their body weight over 48 weeks21

  • human studyThe drug has been shown to improve metabolic health markers, including blood sugar control, hemoglobin A1c, blood pressure, and insulin sensitivity21

  • animalRetatrutide shows superior efficacy compared to other incretin-based therapies in animal studies3

  • animalIn obese mice, administration of LY3437943 decreased body weight and improved glycemic control18

  • animalRetatrutide demonstrated superior effectiveness in reducing weight and improving renal function in db/db mice compared to Liraglutide and Tirzepatide20

  • animalRetatrutide substantially enhanced liver function, reduced triglyceride levels, cholesterol levels, low-density lipoprotein cholesterol, elevated high-density lipoprotein cholesterol, and increased the content of intestinal metabolite butyrate in db/db mice when compared to the other two drugs20

  • animalRetatrutide did not outperform the other two drugs in lowering blood glucose levels20

  • animalRetatrutide was the most effective in improving DKD and body weight20

  • expert opinion5–7% weight loss improves blood glucose levels6

  • expert opinionGreater than 10–15% weight loss is associated with greater benefits, including improved cardiovascular outcomes and possible remission of type 2 diabetes6

  • expert opinionClinical trials including Phase II studies demonstrated significant reductions in body weight and improvements in metabolic parameters such as blood lipid profiles, blood pressure, and HbA1c levels22

  • expert opinionGLP-1-based medicines have established efficacy for type 2 diabetes and obesity25

  • expert opinionGLP-1 receptor agonists provide cardiorenal benefits in select patient populations25

  • theoreticalPreclinical and early-phase clinical data suggests retatrutide may reduce food intake23

How it works

Based on 15 human trial findings, 3 animal findings, 1 in vitro finding, 24 expert opinion findings and 5 theoretical findings.

  • human trialRetatrutide is a novel triple agonist targeting the receptors of glucagon-like peptide 1 (GLP-1), gastric inhibitory polypeptide (GIP), and glucagon2

  • human trialRetatrutide is a novel triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors3

  • human trialRetatrutide's unique molecular structure enables potent activation of GLP-1, GIP, and glucagon receptors3

  • human trialRetatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors5

  • human trialRetatrutide is less potent at the human GCG and GLP-1 receptors (by a factor of 0.3 and 0.4, respectively) and is more potent at the human GIP receptor (by a factor of 8.9) as compared with endogenous receptor ligands5

  • human trialRetatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors5

  • human trialRetatrutide is a GIP, GLP-1, and glucagon triple hormone receptor agonist7

  • human trialRetatrutide is a triple agonist activating the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors10

Show 40 more findings

  • human trialRetatrutide is a GLP-1/glucose-dependent insulinotropic polypeptide and glucagon receptor agonist undergoing phase 3 trials for weight loss in adults with overweight/obesity13

  • human trialRetatrutide is a triple agonist (GLP-1/GIP/glucagon receptor agonist)14

  • human trialRetatrutide has incretin agonist activity15

  • human trialRetatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors16

  • human trialLiver fat reductions were significantly related to changes in body weight, abdominal fat and metabolic measures associated with improved insulin sensitivity and lipid metabolism16

  • human trialRetatrutide is a single peptide with agonist activity at the glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon receptors17

  • human trialLY3437943 is a novel triple agonist peptide at the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R)18

  • animalBody weight loss was augmented by the addition of GCGR-mediated increases in energy expenditure to GIPR- and GLP-1R-driven calorie intake reduction18

  • animalRetatrutide markedly suppressed the expression of pro-inflammatory cytokines (TNF-α, caspase-1, and NLRP3) and pro-fibrotic factors (fibronectin, α-SMA, and collagen I) in the kidneys of mice20

  • animalInhibiting the expression of inflammatory factors and fibrosis mediators and regulating intestinal microbiota may be the potential mechanisms of Retatrutide to delay the progression of DKD20

  • in vitroIn vitro, LY3437943 shows balanced GCGR and GLP-1R activity but more GIPR activity18

  • expert opinionRetatrutide is a novel triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors3

  • expert opinionRetatrutide's unique molecular structure enables potent activation of GLP-1, GIP, and glucagon receptors, leading to significant weight reduction, improved glycemic control, and favorable metabolic outcomes3

  • expert opinionRetatrutide works by targeting three hunger- and metabolism-regulating hormone receptors at the same time: GIP, GLP-1, and glucagon4

  • expert opinionType 2 diabetes is characterised by hyperglycaemia caused by insulin resistance and a decline in pancreatic β-cell function6

  • expert opinionExcess adiposity, especially visceral fat and ectopic fat deposition in liver and skeletal muscle, can lead to insulin resistance and is often associated with type 2 diabetes6

  • expert opinionRetatrutide is a GIP, GLP-1, and glucagon triple hormone agonist6

  • expert opinionTargeting the glucagon receptor has been shown to increase energy expenditure, suppress appetite, and enhance fat metabolism while providing meaningful improvement in glycaemic control6

  • expert opinionRetatrutide is a triple agonist (GIP, GLP-1, glucagon receptors)8

  • expert opinionRetatrutide is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors9

  • expert opinionRetatrutide is a next-generation triple agonist that targets the GLP-1, GIP, and glucagon receptors simultaneously21

  • expert opinionHalf-life determines how long Retatrutide stays active, how often it must be administered, and how consistently it maintains therapeutic effects like appetite suppression, insulin regulation, and energy expenditure21

  • expert opinionRetatrutide is a multi-receptor agonist targeting glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR)22

  • expert opinionRetatrutide exhibits relatively stronger agonistic effect on the GIP receptor while maintaining attenuated activation of GLP-1 and glucagon receptors22

  • expert opinionGLP-1R activation enhances glucose-stimulated insulin secretion, slows gastric emptying, and promotes satiety22

  • expert opinionGIPR activation facilitates insulin secretion in a glucose-dependent manner and plays an important role in lipid metabolism22

  • expert opinionGCGR agonism promotes energy expenditure and modulates hepatic glucose production, leading to increased thermogenesis and lipid mobilization22

  • expert opinionRetatrutide activates GIP, GLP-1, and glucagon receptors23

  • expert opinionGLP-1 works in a glucose-dependent manner to enhance insulin secretion, modulate glucagon secretion, delay gastric emptying, and increase satiety signals in the brain23

  • expert opinionGIP primary role is in enhancing glucose-dependent insulin secretion and also decreases food intake and regulates lipid metabolism23

  • expert opinionGlucagon increases hepatic glucose production during hypoglycemia, increases insulin secretion, reduces food intake, modulates energy expenditure and lipid metabolism, and delays gastric emptying23

  • expert opinionRetatrutide is a novel synthetic molecule which is an agonist of the GIP receptor, GLP-1 receptor, and glucagon receptor23

  • expert opinionRetatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors to amplify metabolic effects24

  • expert opinionRetatrutide represents next-generation GLP-1-based therapeutics engaging multiple gastro-entero-pancreatic hormone receptors24

  • expert opinionRetatrutide enables simultaneous activation of the glucagon and GLP-1 receptors25

  • theoreticalRetatrutide may address key chronic kidney disease (CKD)-related pathophysiological pathways9

  • theoreticalRetatrutide is a GIP, GLP-1 and glucagon receptor agonist19

  • theoreticalPreclinical and early-phase clinical data suggests retatrutide may enhance energy expenditure23

  • theoreticalPreclinical and early-phase clinical data suggests retatrutide may improve lipid metabolism and glucose homeostasis23

  • theoreticalPreclinical and early-phase clinical data suggests retatrutide may reduce inflammation23

Dosing

Based on 9 human trial findings, 6 human study findings and 5 expert opinion findings.

  • human trialOnce-weekly subcutaneous retatrutide was studied in placebo-controlled, randomized clinical trials1

  • human trialSubcutaneous retatrutide was administered once weekly for 48 weeks at doses of 1 mg, 4 mg, 8 mg, or 12 mg5

  • human trialSubcutaneous dosing once weekly5

  • human trialThe trial investigated the efficacy and safety of retatrutide (4 mg, 9 mg, or 12 mg) compared with placebo as a monotherapy for 40 weeks6

  • human trialParticipants were randomized 1:1 to once-weekly retatrutide maximum tolerated dose up to 12 mg or matched placebo9

  • human trialTRIUMPH consists of four Phase 3, multicenter, randomized, double-blind studies assessing weekly subcutaneous retatrutide compared to placebo10

  • human trialRetatrutide administered as weekly subcutaneous injection10

  • human trialDosing was once-weekly subcutaneous retatrutide at 1, 4, 8 or 12 mg16

Show 12 more findings

  • human trialParticipants were treated with once-weekly injections17

  • human studyRetatrutide can be given as a once-weekly injection21

  • human studyRetatrutide is administered as a once-weekly subcutaneous injection21

  • human study1 mg per week – Lowest dose, primarily studied for tolerability. Showed modest effects on weight reduction.21

  • human study4 mg per week – Intermediate dose, with improved weight loss but still below the top-tier results.21

  • human study8 mg per week – Produced significant reductions in body weight, making it a potential therapeutic sweet spot.21

  • human study12 mg per week – Highest studied dose; associated with the largest weight loss outcomes21

  • expert opinionRetatrutide is given as a once-weekly injection under the skin (subcutaneous injection)4

  • expert opinionThe American Diabetes Association recommends a glycated haemoglobin (HbA1c) target of less than 7% (<53 mmol/mol) for most individuals6

  • expert opinionThe American Diabetes Association endorses more stringent HbA1c targets (eg, <6·5% [<48 mmol/mol]) for individuals with shorter disease duration, good overall health, longer life expectancy, and low treatment-related risks6

  • expert opinionCareful patient selection, dose titration, and monitoring are crucial for patients with GI disorders, hypersensitivity, hepatic disease, cardiac disease8

  • expert opinionRetatrutide follows a titration model, meaning the dose is gradually increased over time to improve tolerability and minimize gastrointestinal side effects21

How the body handles it

Based on 4 human trial findings and 1 expert opinion finding.

  • human trialThe mean half-life was about 6 days3

  • human trialThe pharmacokinetics of retatrutide are considered dose-proportional5

  • human trialRetatrutide has a half-life of approximately 6 days, which enables weekly administration5

  • human trialIts pharmacokinetic profile supported once-weekly dosing18

  • expert opinionRetatrutide is a single peptide coupled to a fatty diacid moiety that prolongs its half-life and allows for once-weekly administration22

Safety and side effects

Based on 28 human trial findings, 1 human study finding and 1 expert opinion finding.

  • human trialOnce-weekly subcutaneous retatrutide significantly increased non-severe gastrointestinal and hypersensitivity adverse events1

  • human trialCommon adverse effects of retatrutide are primarily gastrointestinal and dose-related3

  • human trialThe most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg)5

  • human trialDose-dependent increases in heart rate peaked at 24 weeks and declined thereafter5

  • human trialMost common adverse events were gastrointestinal, dose-related, mostly mild to moderate severity, partially mitigated with lower starting dose (2 mg vs. 4 mg)5

  • human trialDose-dependent increases in heart rate peaked at 24 weeks and declined thereafter5

  • human trialThe most frequent adverse events with retatrutide were generally mild to moderate gastrointestinal events, which subsided over time7

  • human trialStudy intervention discontinuations due to adverse events were 2-5% with retatrutide and 0% with placebo7

Show 22 more findings

  • human trialNo severe hypoglycaemia was reported7

  • human trialTwo deaths occurred during the study, both in the retatrutide 4 mg group and unrelated to the study drug7

  • human trialRetatrutide significantly increased the incidence of adverse events compared to placebo (RR 1.87; 95% CI 1.25-2.80; p=0.003)8

  • human trialGastrointestinal disturbances (nausea, decreased appetite, vomiting, constipation) are the most common adverse events8

  • human trialNo significant difference in serious adverse events was observed between retatrutide and placebo (RR 0.81; 95% CI 0.36-1.83; p=0.61)8

  • human trialAdverse events of special interest, such as hypersensitivity and pancreatitis, were notably higher in the retatrutide group (RR 2.94; 95% CI 1.85-4.69; p<0.00001)8

  • human trialTreatment-emergent adverse events (TEAEs) and gastrointestinal adverse events, particularly nausea, vomiting, and constipation, were more frequent with retatrutide11

  • human trialAdverse events were frequent with GLP-1 RAs and co-agonists (80% to 97% vs placebo 63% to 100%), with majority being gastrointestinal-related (47% to 84% vs placebo 13% to 63%)12

  • human trialMost common adverse events were nausea, vomiting, diarrhea, and constipation12

  • human trialAdverse events requiring treatment discontinuation (0% to 26% vs placebo 0% to 9%) and serious adverse events (0% to 10% vs placebo 0% to 12%) were rare12

  • human trialRetatrutide causes rapid and significant loss of lean mass (∼10% or ∼6 kg)15

  • human trialMild-to-moderate gastrointestinal adverse events, including nausea, diarrhoea, vomiting, and constipation, were reported in 67 (35%) of 190 participants in the retatrutide groups17

  • human trialGastrointestinal adverse events occurred in 6 (13%) of 47 in the 0.5 mg group17

  • human trialGastrointestinal adverse events occurred in 12 (50%) of 24 in the 8 mg fast escalation group17

  • human trialGastrointestinal adverse events occurred in 6 (13%) of 45 participants in the placebo group17

  • human trialGastrointestinal adverse events occurred in 16 (35%) of 46 participants in the 1.5 mg dulaglutide group17

  • human trialThere were no reports of severe hypoglycaemia during the study17

  • human trialThere were no deaths during the study17

  • human trialRetatrutide showed a safety profile consistent with GLP-1 receptor agonists and GIP and GLP-1 receptor agonists17

  • human trialIn a phase 1 single ascending dose study, LY3437943 showed a safety and tolerability profile similar to other incretins18

  • human studyCommon adverse effects are primarily gastrointestinal and dose-related3

  • expert opinionRetatrutide is not FDA approved and is only available to participants in clinical trials4

What people use it for

Based on 4 human trial findings, 3 animal findings and 7 expert opinion findings.

  • human trialPhase 2, double-blind, randomized, placebo-controlled trial in adults with BMI ≥30 or BMI 27-29.9 plus weight-related condition5

  • human trialTRANSCEND-CKD is a double-blind, placebo-controlled, Phase 2b mechanistic study evaluating the efficacy of retatrutide in adults with overweight/obesity and CKD9

  • human trialRetatrutide is a premarket agent for long-term weight management12

  • human trialRetatrutide has progressed to phase 3 trials as an obesity treatment14

  • animalAnimal studies demonstrate retatrutide's ability to delay gastric emptying, reduce food intake, and promote weight loss3

  • animalAnimal studies demonstrate retatrutide's ability to delay gastric emptying, reduce food intake, and promote weight loss, with superior efficacy compared to other incretin-based therapies3

  • animalRetatrutide has been investigated in animal studies for effectiveness in obesity and diabetes19

  • expert opinionRetatrutide is an investigational triple hormone receptor agonist being developed for weight loss in the treatment of obesity and overweight people with weight-related medical problems4

Show 6 more findings

  • expert opinionChronic progression of type 2 diabetes leads to macrovascular and microvascular complications, including cardiovascular disease6

  • expert opinionTRANSCEND-T2D-1 is the first phase 3 clinical trial of retatrutide for the treatment of type 2 diabetes6

  • expert opinionCurrent guidelines advocate for a primary target of 5-15% weight loss in diabetes management, with over 10-15% potentially inducing remission of type 2 diabetes8

  • expert opinionRetatrutide is not yet approved for general medical use and remains in Phase 3 clinical trials21

  • expert opinionRetatrutide is being explored for obesity management, type 2 diabetes mellitus, non-alcoholic fatty liver disease, and metabolic dysregulation conditions22

  • expert opinionGLP-1-based medicines are being investigated for metabolic liver disease, peripheral artery disease, Parkinson disease, and Alzheimer disease25

Other findings

Based on 3 expert opinion findings.

  • expert opinionRetatrutide is compared with other dual or single receptor agonists19

  • expert opinionRetatrutide is compared with DPP-4 inhibitors19

  • expert opinionAnalysts expect regulatory submission around 2026, with potential market availability in late 2026 or 202721

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Limited evidence

Most human efficacy data come from phase 1/2 trials; phase 3 results are still emerging.

Several sources note retatrutide remains investigational and not FDA approved, available only in clinical trials, with phase 3 TRIUMPH and TRANSCEND studies still ongoing; the largest weight-loss figures (e.g. 28.3% at 80 weeks) come from Drugs.com summaries of phase 3 TRIUMPH data rather than peer-reviewed primary reports.

Preprint

One meta-analysis of pooled efficacy is a preprint.

The reported pooled reductions (HbA1c 0.9%, FBG 21.87 mg/dL, body weight 10.66 kg, BMI 4.55 kg/m²) come from a Research Square preprint (rs.3.rs-7103001/v1) that has not completed peer review.

Contested

In animals, retatrutide did not beat comparators on glucose lowering despite superior weight/renal effects.

A db/db mouse study found retatrutide was the most effective for weight and diabetic kidney disease and superior to liraglutide and tirzepatide overall, but specifically did not outperform those two drugs in lowering blood glucose.

Single source

Significant lean mass loss is reported by only one review.

A single review reports retatrutide causes rapid and significant loss of lean mass (~10% or ~6 kg), a safety signal not quantified elsewhere in the sources.

Other

Vendor/blog sources give promotional framing and forecasts, not trial data.

Lower-tier web/vendor sources (Swolverine, patsnap) provide dosing narratives, an '8 mg sweet spot' characterization, and market-timing forecasts (submission ~2026, availability 2026/2027) that are expert speculation rather than trial findings.

Single source

Elevated hypersensitivity and pancreatitis signal comes from one meta-analysis.

Only one meta-analysis (4 studies) reports that adverse events of special interest such as hypersensitivity and pancreatitis were notably higher with retatrutide (RR 2.94; 95% CI 1.85–4.69), while finding no significant difference in serious adverse events overall.

Safety and side effects

Safety and Side Effects

Retatrutide is investigational and not FDA approved; it is available only to clinical trial participants. The safety data below come from trials, meta-analyses and reviews.

Gastrointestinal effects

Trial reports note that the most common adverse events with retatrutide were gastrointestinal, dose-related, mostly mild to moderate, and partially mitigated with a lower starting dose (2 mg vs 4 mg). In the phase 2 type 2 diabetes trial, mild-to-moderate gastrointestinal adverse events occurred in 67 (35%) of 190 participants in the retatrutide groups—ranging from 13% in the 0.5 mg group to 50% in the 8 mg fast-escalation group—versus 13% with placebo and 35% with 1.5 mg dulaglutide, with no severe hypoglycaemia and no deaths. In TRANSCEND-T2D-1, gastrointestinal adverse events were generally mild to moderate and subsided over time; discontinuations due to adverse events were 2–5% with retatrutide versus 0% with placebo, no severe hypoglycaemia was reported, and two deaths (both in the 4 mg group) were unrelated to the study drug. A preprint meta-analysis noted more frequent treatment-emergent and gastrointestinal adverse events, particularly nausea, vomiting and constipation.

Adverse events of special interest

A meta-analysis (4 studies) reported retatrutide significantly increased the incidence of adverse events versus placebo (RR 1.87; 95% CI 1.25–2.80; p=0.003) and increased adverse events of special interest such as hypersensitivity and pancreatitis (RR 2.94; 95% CI 1.85–4.69; p<0.00001), while finding no significant difference in serious adverse events (RR 0.81; 95% CI 0.36–1.83; p=0.61). This hypersensitivity/pancreatitis signal comes from a single meta-analysis. Another meta-analysis found retatrutide significantly increased non-severe gastrointestinal and hypersensitivity adverse events. Across GLP-1 RAs and co-agonists, one review reports adverse events were frequent (80–97% vs placebo 63–100%), mostly gastrointestinal (47–84% vs placebo 13–63%), while events requiring discontinuation (0–26% vs placebo 0–9%) and serious adverse events (0–10% vs placebo 0–12%) were rare.

Cardiovascular and lean mass

Trial reports note dose-dependent increases in heart rate that peaked at 24 weeks and declined thereafter. One review reports that retatrutide induces approximately 15–24% weight loss with beneficial impacts on blood pressure, cholesterol, blood glucose and insulin, but also causes rapid and significant loss of lean mass (approximately 10% or about 6 kg)—a signal quantified by only that single review.

Monitoring

A journal review advises that careful patient selection, dose titration and monitoring are crucial for patients with GI disorders, hypersensitivity, hepatic disease or cardiac disease. Reviews note ongoing phase 3 TRIUMPH trials aim to further evaluate retatrutide's long-term safety and efficacy in diverse populations, describing common adverse effects as primarily gastrointestinal and dose-related.

Reconstitution and handling

Dosing

No dose has been established for general use. Retatrutide is investigational and not FDA approved; per Drugs.com it is available only to clinical trial participants, so no regulatory label exists. The figures below are what trials and other sources report—not guidance.

How it was dosed in trials

  • Retatrutide is administered as a once-weekly subcutaneous injection. A mechanism review attributes the once-weekly schedule to a fatty diacid moiety that prolongs its half-life (~6 days), with dose-proportional pharmacokinetics reported by the NEJM phase 2 trial.
  • The NEJM phase 2 obesity trial administered retatrutide once weekly for 48 weeks at 1, 4, 8 or 12 mg, with a lower 2 mg starting dose used for titration.
  • The phase 3 TRANSCEND-T2D-1 trial tested 4, 9 or 12 mg as monotherapy over 40 weeks.
  • A phase 2 type 2 diabetes trial used 0.5, 4, 8 and 12 mg with various escalation schedules (slow and fast escalation to 8 mg).
  • Trial reports note that gastrointestinal adverse events were dose-related and partially mitigated by using a lower starting dose (2 mg vs 4 mg), consistent with a titration model of gradually increasing doses.

Vendor framing (lower-tier)

A vendor blog describes retatrutide as a once-weekly subcutaneous triple agonist given via a titration model, characterizing 1 mg as the lowest tolerability dose, 4 mg as intermediate, 8 mg as a "potential therapeutic sweet spot," and 12 mg as the highest dose associated with the largest weight loss (participants at higher doses losing up to an average of 24% of body weight over 48 weeks). This "sweet spot" characterization is promotional narrative rather than a trial finding.

Reconstitution note

The sources provided do not describe reconstitution of a lyophilized product; trial and label descriptions refer to a subcutaneous injection. Any reconstitution arithmetic (volume of bacteriostatic water per vial and resulting concentration) is a calculation about a specific container and is not addressed by these sources.

Glycemic targets referenced

A Lancet review notes the American Diabetes Association recommends an HbA1c target of less than 7% (<53 mmol/mol) for most people, with a more stringent target (e.g. <6.5% [<48 mmol/mol]) for those with shorter disease duration, good health, longer life expectancy and low treatment-related risk.

Sources

Ordered by evidence quality — the strongest first.

  1. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials(opens in a new tab)
    Tier 1Web · sciencedirect.com
  2. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon ...(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  3. Retatrutide—A Game Changer in Obesity Pharmacotherapy(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  4. Retatrutide: Uses, Dosing, Side Effects, Weight Loss Results(opens in a new tab)
    Tier 1Web · drugs.com
  5. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial(opens in a new tab)
    Tier 1Web · nejm.org
  6. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial - ScienceDirect(opens in a new tab)
    Tier 1Web · sciencedirect.com · 2026
  7. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial - PubMed(opens in a new tab)
    Tier 1Web · pubmed.ncbi.nlm.nih.gov · 2026
  8. Navigating retatrutide safety: comprehensive insights from systematic review and meta-analysis(opens in a new tab)
    Tier 1Web · doi.org · 2026
  9. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  10. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  11. Efficacy and safety of retatrutide for overweight/obesity or type 2 diabetes: a systematic review and meta-analysis(opens in a new tab)
    Tier 1Web · doi.org · 2025
  12. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  13. Emerging pharmacotherapies for obesity: A systematic review.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  14. What is the pipeline for future medications for obesity?(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  15. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  16. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  17. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  18. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  19. The power of three: Retatrutide's role in modern obesity and diabetes therapy - ScienceDirect(opens in a new tab)
    Tier 2Web · sciencedirect.com
  20. Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  21. Retatrutide Half-Life: Duration, Dosage, Clearance Time, And Compariso – Swolverine(opens in a new tab)
    Tier 3Web · swolverine.com
  22. What is the mechanism of action of Retatrutide?(opens in a new tab)
    Tier 3Web · synapse.patsnap.com
  23. What is the mechanism of action of retatrutide?undefined(opens in a new tab)
    Tier 3Web · medical.lilly.com
  24. Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  25. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2024